Specific Biologics closed a $35 million Series A to advance its Dualase gene-editing therapy through early clinical testing in ALS patients.
- Amount
- $35M
- Stage
- Series A
- Announced
- 2 November 2026
- Lead
- Hatteras Venture Partners
- Other investors
- Lumira Ventures, adMare BioInnovations, Genesys Capital, Business Development Bank of Canada's (BDC) Life Sciences Venture Fund, DeepWork Capital, Seido Capital
- Use of funds
- Advance lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in ALS patients.
- Checked
- Matched to an official SEC filing